Drug intelligence / Profile preview

OMTX103

Development stage: Preclinical
Lead developer: Oncomatryx
Modality: Small Molecules
Administration: Sublingual, Oral

Overview

**OMTX103** is a tubulin inhibitor and UMOD modulator developed by Oncomatryx Biopharma SL for the treatment of solid tumors. It represents an investigational cancer therapeutic with a novel mechanism targeting tubulin polymerization and UMOD (uromodulin) pathways to disrupt cancer cell proliferation and tumor microenvironment dynamics. Early research is underway, focusing on its potential in advanced solid malignancies.[11][12]

Targets

TUBB (Tubulin (alpha and beta subunits))UMOD (Uromodulin)

Beyond the preview

Go deeper on OMTX103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMTX103.

Explore the full profile